Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VSTMBOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of stock options to purchase 73,000 shares of its common stock to eight new employees and the grant of 218,265 restricted stock units to nineteen new employees. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee’s acceptance of emplo
Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
VSTMBOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that following evaluation of interim data from the RAMP 203 clinical trial in advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) it will discontinue the trial to focus resources on clinical development of VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, in advanced NSCLC and other solid tumors. The
Verastem Oncology to Present at Upcoming Investor Conferences
VSTMBOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate and present at the following investor conferences in September: Cantor Global Healthcare Conference 2025: Fireside chat on Wednesday, September 3 at 3:55 pm ET H.C. Wainwright 27th Annual Global Investment Conference: Fireside chat on Monday, September 8
Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics’ Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer
VSTMBOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK-pathway-driven cancers, today announced positive, updated safety and efficacy data and late-breaking presentation details of partner GenFleet Therapeutics’ Phase 1/2 study in China of GFH375, an oral KRAS G12D (ON/OFF) inhibitor, known as VS-7375 outside of China, in advanced non-small cell lung cancer patients with a KRAS G12D mutation. The data
Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates
VSTMBOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced business updates and reported financial results for the second quarter ended June 30, 2025. “In the second quarter of 2025, AVMAPKI FAKZYNJA CO-PACK became the first-ever treatment approved by the FDA specifically for use in patients with KRAS-mutated recurrent low-grade serous ovarian cancer, and we are of
What's Going On With Verastem Oncology Stock On Monday?
VSTMVerastem's GFH375 trial data at ASCO 2025 shows a 52% response rate in pancreatic cancer and no dose-limiting toxicities across tested doses.
Verastem Oncology Announces Updated Data From Dose Escalation Phase Of The Phase 1/2 Trial Of GFH375; Study Shows ORR Of 52% In Patients With Pancreatic Ductal Adenocarcinoma And ORR Of 42% With Non-Small Cell Lung Cancer
VSTMVerastem Oncology's Phase 2 Dose Level 1 Shows 83% Overall Response Rate In Frontline Metastatic Pancreatic Ductal Adenocarcinoma
VSTMVerastem Reveals Updated Results From RAMP 205 Evaluating Avutometinib Plus Defactinib In Combination With Standard-Of-Care Chemotherapy In Frontline Metastatic Pancreatic Ductal Adenocarcinoma
VSTMVerastem Q1 Adj. EPS $(0.79) Misses $(0.71) Estimate
VSTMHC Wainwright & Co. Maintains Buy on Verastem, Raises Price Target to $14
VSTMFDA Grants Accelerated Approval To Verastem's Combination Drug For Ovarian Cancer
VSTMFDA grants accelerated approval to Verastem's Avmapki Fakzynja for KRAS-mutated ovarian cancer; company plans $75 million funding for future developments.
Verastem Shares Resume Trade
VSTMTrading Halt: Halt status updated at 1:40:00 PM ET: Quotation Resumption: News and Resumption Times
VSTM'FDA Grants Accelerated Approval To The Combination Of Avutometinib And Defactinib For KRAS-Mutated Recurrent Low-grade Serous Ovarian Cancer'
VSTMTrading Halt: Halted at 11:10:03 a.m. ET - Trading Halt: Halt News Pending
VSTMVerastem Oncology Announces $75M Private Placement
VSTMJefferies Initiates Coverage On Verastem with Buy Rating, Announces Price Target of $15
VSTMMizuho Maintains Outperform on Verastem, Lowers Price Target to $8
VSTMGuggenheim Maintains Buy on Verastem, Raises Price Target to $14
VSTMHC Wainwright & Co. Maintains Buy on Verastem, Raises Price Target to $10
VSTMRBC Capital Maintains Outperform on Verastem, Lowers Price Target to $14
VSTMVerastem Q4 Adj $(0.60) Beats $(0.81) Estimate
VSTMVerastem Licenses KRAS G12D Inhibitor VS-7375 Early, Reports Phase 1 Data from GenFleet Study
VSTMVerastem Secures $150M Credit Facility and $7.5M Equity Investment to Advance Cancer Treatments
VSTMMizuho Maintains Outperform on Verastem, Raises Price Target to $9
VSTMHC Wainwright & Co. Reiterates Buy on Verastem, Maintains $7 Price Target
VSTMVerastem Q3 Adj $(0.88) Misses $(0.74) Estimate
VSTMVerastem Oncology Completes Rolling NDA Submission To The FDA For Avutometinib Plus Defactinib As A Treatment For Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer; Seeking Accelerated Approval And Priority Review Of Its NDA Submission In Patients Wit
VSTM